Search Page

1

Cite

Share

[CT-Screening for Lung Cancer - what is the Evidence?].

Watermann I, Reck M. Watermann I, et al. Dtsch Med Wochenschr. 2018 Apr;143(7):494-497. doi: 10.1055/s-0043-104919. Epub 2018 Apr 3. Dtsch Med Wochenschr. 2018. PMID: 29614540 German.

Cite

Share

2

Cite

Share

Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas.

Pasternack H, Kuempers C, Deng M, Watermann I, Olchers T, Kuehnel M, Jonigk D, Kugler C, Stellmacher F, Goldmann T, Kirfel J, Ammerpohl O, Perner S, Reck M. Pasternack H, et al. Among authors: watermann i. Sci Rep. 2021 May 5;11(1):9532. doi: 10.1038/s41598-021-89030-9. Sci Rep. 2021. PMID: 33953302 Free PMC article.

Cite

Share

3

Cite

Share

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler Ch, Reinmuth N, Huber RM, Thomas M, Zabel P, Rabe KF, Jonigk D, Warth A, Vollmer E, Reck M, Goldmann T. Watermann I, et al. Diagn Pathol. 2015 Jul 28;10:130. doi: 10.1186/s13000-015-0362-5. Diagn Pathol. 2015. PMID: 26215852 Free PMC article.

Cite

Share

4

Cite

Share

Activation of CD95L fusion protein prodrugs by tumor-associated proteases.

Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, Wajant H. Watermann I, et al. Cell Death Differ. 2007 Apr;14(4):765-74. doi: 10.1038/sj.cdd.4402051. Epub 2006 Oct 20. Cell Death Differ. 2007. PMID: 17053806

Cite

Share

5

Cite

Share

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.

Gaber R, Watermann I, Kugler C, Reinmuth N, Huber RM, Schnabel PA, Vollmer E, Reck M, Goldmann T. Gaber R, et al. Among authors: watermann i. Diagn Pathol. 2014 Sep 17;9:165. doi: 10.1186/s13000-014-0165-0. Diagn Pathol. 2014. PMID: 25227424 Free PMC article.

Cite

Share

6

Cite

Share

Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B. Kayser S, et al. Among authors: watermann i. J Cancer Res Clin Oncol. 2003 Jul;129(7):397-409. doi: 10.1007/s00432-003-0445-7. Epub 2003 Jun 26. J Cancer Res Clin Oncol. 2003. PMID: 12836015

Cite

Share

7

Cite

Share

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanoviç S, Wallwiener D, Gückel B. Rentzsch C, et al. Among authors: watermann i. Clin Cancer Res. 2003 Oct 1;9(12):4376-86. Clin Cancer Res. 2003. PMID: 14555509

Cite

Share

8

Cite

Share

[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients].

Reinmuth N, Heigener D, Goldmann T, Watermann I, Reck M. Reinmuth N, et al. Among authors: watermann i. Pneumologie. 2014 Sep;68(9):619-23. doi: 10.1055/s-0034-1377927. Epub 2014 Sep 9. Pneumologie. 2014. PMID: 25203821 Free article. Clinical Trial. German.

Cite

Share

9

Cite

Share

Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data.

Gaber R, Watermann I, Kugler C, Vollmer E, Perner S, Reck M, Goldmann T. Gaber R, et al. Among authors: watermann i. Rom J Morphol Embryol. 2017;58(4):1175-1184. Rom J Morphol Embryol. 2017. PMID: 29556606 Free article.

Cite

Share